Epidemiology
Total 0–14 15–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75+ Crude ASR(W) Both 337,872 0.0 0.2 1.3 3.1 6.1 10.4 16.5 24.0 32.5 55.7 4.8 4.2 Men 178,161…
Mesenteric Approach for Pancreaticoduodenectomy
Fig. 17.1 The superior mesenteric artery (SMA) and superior mesenteric vein (SMV) are identified at the infracolic mesentery. The middle colic artery is usually divided if cancer invasion is severe…
Personalized Peptide Vaccine for Advanced Pancreatic Cancer
Fig. 40.1 New types of peptide-based vaccines: Examples of new types of peptide-based vaccines are shown. Gray and black boxes indicate CTL and helper T-cell epitopes, respectively 40.2 No Impact…
Radiation Therapy
Trial Treatment n Median survival month) Overall survival (%) GITSG [9, 10] Chemoradiation 21 21 14 (5 years) Observation 22 10.9 4 (5 years) Chemoradiation(additional study) 30 18 46 (2…
Guidelines for the Management of Pancreatic Cystic Neoplasms
Fig. 12.1 Magnetic resonance cholangiopancreatogram showing multiple branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) Fig. 12.2 Magnetic resonance cholangiopancreatogram demonstrating a mucinous cystic neoplasm (MCN) 12.2 Guidelines for the Management…
Current Issues of Borderline Resectable Pancreatic Ductal Adenocarcinoma
Fig. 11.1 Schema for initial evaluation and categorization of patients with pancreatic adenocarcinoma 11.1.4 Stratification Using MDACC Borderline Patient Types In practice, the fitness of each patient for pancreatic surgery…
PET and Other Functional Imaging
Fig. 9.1 FDG PET/CT imaging of a patient with pancreatic adenocarcinoma. Primary tumor is located at uncinate process of the pancreas. Whole body projection image and PET/CT tomography reveal metastasis…
Chemotherapy in the Management of Pancreatic Cancer
Study/authorpublication year Launched date Study design N LAPDAC (%) Gem DI (%) Median (95% CI) survival, months ORR (%) PFS OS I. Gemcitabine vs. non-gemcitabine-containing regimens in advanced pancreatic cancer…
Drain Management After Pancreatectomy
Authors Year Study design Procedure Variable Sample size Morbiditya (%) Pancreatic fistulab (%) Re-drainage (%) Reoperation (%) Readmission (%) Mortality (%) Conlon et al. [11] 2001 RCT PD and DP…
Enhanced Recovery Program After Pancreatectomy
Fig. 35.1 ERAS elements [32] Major abdominal surgery induces an immune-inflammatory response, which is accompanied by the production of reactive oxygen species (ROS) at the site of injury causing direct…
